摘要
Objectives: In the phase 3 CheckMate 078 study, nivolumab prolonged overall survival (OS) and showed a favorable safety profile versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (aNSCLC). However, long-term efficacy, safety, and health-related quality of life findings with second-line nivolumab are very limited in Asian patients with previously treated aNSCLC. Here,we report updated clinical data and patient-reported outcomes (PROs) from the phase 3 CheckMate 078 trial with a 3-year minimum follow-up. @@@ Materials and methods: Patients with aNSCLC and disease progression after platinum-doublet chemotherapy were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m(2) every 3 weeks) until progression or unacceptable toxicity. The primary endpoint was OS; secondary endpoints included objective response rate, progression-free survival, safety, and disease-related symptom deterioration assessed using the Lung Cancer Symptom Scale (LCSS) by Week 12. Additional PRO assessments were exploratory endpoints. @@@ Results: At >= 37.3 months follow-up, 3-year OS rates were 19% with nivolumab and 12% with docetaxel; 30% and 0% of responders remained in response for >= 3 years, respectively. Incidence of treatment-related adverse events occurring after 2 years was lower than during the first 2 years. No new treatment-related deaths were reported. By Week 12 of treatment, rates of disease-related symptom deterioration were 32% with nivolumab and 47% with docetaxel. Completion rates for PRO questionnaires were >= 80% in both arms. Clinically meaningful and sustained improvements in LCSS Average Symptom Burden Index scores and delayed time to first symptom deterioration were observed with nivolumab against docetaxel. @@@ Conclusions: At 3 years, nivolumab continued to demonstrate survival benefit versus docetaxel, exhibiting improvements in disease-related symptoms and overall health status in a predominantly Chinese patient population with previously treated aNSCLC. No new safety signals were observed. These findings are similar to the global population.
学科与关键词
- Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Lu, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai-Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jian-Ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Ying, Kejing; Zhong, Hua; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Li, Ang; Li, Amy; Wu, Yi-Long*Lung Cancer, 2021, 152: 7-14.被引 35
- An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)Lu, Shun*; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, JianhuaTherapeutic Advances in Medical Oncology, 2022, 14.被引 2
- Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term resultsLu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
